This integrated bioinformatic analysis demonstrated that GATA1-4, and 6 may be new prognostic biomarkers, and GATA2/5/6 may be potential targets for personalized therapy for patients with LC. This evidence concerns the gene GATA1 and laryngotracheoesophageal cleft.